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Abstract
Background: Characterization of novel fusion genes in acute leukemia is important for gaining information about
leukemia genesis. We describe the characterization of a new ETV6 fusion gene in acute myeloid leukemia (AML)
FAB M0 as a result of an uncommon translocation involving chromosomes 12 and 15.
Methods: The ETV6 locus at 12p13 was shown to be translocated and to constitute the 5’ end of the fusion
product by ETV6 break apart fluorescence in situ hybridisation (FISH). To identify a fusion partner 3’ rapid
amplification of cDNA-ends with polymerase chain reaction (RACE PCR) was performed followed by cloning and
sequencing.
Results: The NTRK3 gene on chromosome 15 was found to constitute the 3’ end of the fusion gene and the
underlying ETV6-NTRK3 rearrangement was verified by reverse transcriptase PCR. No RNA of the reciprocal NTRK3-
ETV6 fusion gene could be detected.
Conclusion: We have characterized a novel ETV6-NTRK3 fusion transcript which has not been previously described
in AML FAB M0 by FISH and RACE PCR. ETV6-NTRK3 rearrangements have been described in secretory breast
carcinoma and congenital fibrosarcoma.
Background
Chromosomal translocations resulting in fusion genes
with transforming activity are fundamental in leukemia
genesis. The ETV6 gene (ETS variant gene 6) on the
short arm of chromosome 12 encodes a transcriptional
repressor of the ETS transcription factor family which is
fundamental in adult hematopoiesis and plays a versatile
role in hematological malignancies [1]. ETS family mem-
bers are essential for a variety of cellular processes
including proliferation, differentiation, migration and tis-
sue remodeling, angiogenesis, apoptosis, as well as
hematopoiesis and cell transformation [2,3]. ETV6 is a
452 amino acid protein encoded by 8 exons containing
the characteristic ETS domain at its carboxy terminus
[4,5]. The ETS domain harbors DNA binding properties
but also mediates protein-protein interactions [1]. ETV6
contains a helix-loop-helix (HLH) domain at its amino
terminus which mediates homotypic oligomerization of
ETV6 molecules and also heterotypic interactions with
other proteins [1,2]. ETV6 is located on band 12p13
which is genetically unstable and thus susceptible to
chromosomal rearrangements [6]. In recent years ETV6
was shown to be involved in a variety of translocations
associated with hematological malignancies of both mye-
loid as well as lymphoid origin [1,7]. The diversity of
ETV6 rearrangements is striking considering that the
breakpoints do not cluster within a particular region of
the gene [4].
Fusions between ETV6 and phospho-tyrosinkinases
(PTKs) are found in a variety of hematological diseases
where the HLH domain is essential for the aberrant
function of the fusion product, e.g. chronic myelomono-
cytic leukemia (CMML), AML, acute lymphoid leukemia
(ALL) or myelodysplastic syndrome (MDS) [1]. In other
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gulation of cellular functions by its ETS domain [8].
In the present study we identified the PTK NTRK3 as
an ETV6 fusion partner. NTRK3 is a membrane
anchored tyrosine kinase and functions as a receptor for
the neurotrophin NT-3, regulating development and
maintenance of the vertebrate nervous system [9,10].
NTRK3 does not only show expression in neural tissues
but also in hematopoietic and epithelial cells [10].
The NTRK3 gene is composed of 18 exons; the recep-
tor kinase domain is encoded by exons 13 through 18.
Alternative splicing of NTRK3 leads to different iso-
forms, one of which is a truncated version of the full-
length protein and does not possess a catalytically active
kinase domain but exhibits exons 13b and 14b as its
final two exons [9]. The catalytically active ETV6-
NTRK3 fusion proteins have been previously detected in
non-hematopoietic tumors, e.g. secretory breast carci-
noma and congenital fibrosarcoma and in only one sin-
gle case of hematological malignancy, i.e. an AML
[11-13].
Methods
Patient profile
The 55-year-old male patient was transferred to our
department with a newly diagnosed AML-M0 according
to the FAB-classification. The bone marrow showed a
45% infiltration with AML-blasts, which stained positive
for CD33, CD13, CD56 and CD7. Due to that, the
patient received a treatment consisting of one induction
of cytarabine and idarubicin followed by a second induc-
tion of cytarabine and mitoxantrone, a salvage therapy
consisting of cytarabine and fludarabine followed by two
cycles of gemtuzumab ozogamicine. The leukemic clone
was refractory after each treatment cycle with an
unchanged blast count in the bone marrow and the
patient subsequently died after a short period of best
supportive care.
Molecular and cytogenetic diagnostics
The patient was tested negative for mutations of the
NPM1 and FLT3 genes and AML1-ETO-a n dCBFb-
MYH11 rearrangements.
Conventional karyotyping using GTG banding of unsti-
mulated bone marrow cultures showed a pathological
cell line exhibiting monosomy 7 and a translocation t
(10;12)(q24;p13). An ETV6 rearrangement was assumed
and could be demonstrated by Dual Color Break Apart
FISH (LSI
® ETV6 probe; Abbott Molecular) (Figure 1A).
Whole chromosome paints (WCPs) (XCP Human Chro-
mosomen Paints; Metasystems) revealed additional mate-
rial of chromosome 12 on a second chromosome due to
a cryptic translocation; chromosome 15 could be identi-
fied as a partner. (Figure 1B)
RACE PCR method
3’ nested RACE PCR was performed with the GeneRa-
cerTM Kit (Invitrogen) according to the manufacturer
protocol. Primers ETV6A/nested, ETV6B/nested and
ETV6C/nested were used (ETV6 GenBank Accession
number NM_001987, Version NM_001987.4, see Addi-
tional file 1 Table S1 for sequence information) with
Platinum
® Taq DNA Polymerase High Fidelity (Invitro-
gen; 5 U/μl).
Nested RACE PCR products of interest were excised
from the gel and cloned using the TOPO TA Cloning
®
Kit (Invitrogen) according to the manufacturer’s
recommendations.
Amplification of cloned RACE PCR products was per-
formed with 0,5 - 1,0 ng plasmid DNA, M13F/R primers
and AmpliTaq Gold™DNA Polymerase (5 U/μl; Applied
Biosystems). PCR products were purified using the Exo-
SAP-IT
® system (USB) and subsequently sequenced
using the BigDye
® Terminator v1.1 Cycle Sequencing
Kit (Applied Biosystems). Capillary electrophoresis was
r u ni nt h eA B I3 1 3 0G e n e t i cA n a l y z e r( A p p l i e d
Biosystems).
Reverse transcriptase PCR for expression testing
cDNA was prepared from total RNA by random hex-
amer priming (Amersham Biosciences) using M-MLV
RT as indicated by the manufacturer (Promega).
For reverse-transcriptase PCR reactions cDNA was used
undiluted with specifically designed primers for ETV6
(ETV6 GenBank Accession number NM_001987, Version
NM_001987.4) and NTRK3 exons (GenBank Accession
number NM_001012338, version NM_001012338.1
and GenBank Accession number NM_001007156, version
NM_001007156.1) as listed in the Additional file 1
Table S1.
Results and Discussion
Genetic alterations play a key role in the pathogenesis of
both solid tumors and hematological malignancies. In
recent years the description of these alterations by mole-
cular genetics provided crucial information for risk stra-
tification and therapy, especially for acute leukemias.
We describe a novel ETV6 fusion in an AML patient,
which was confirmed by FISH and WCP (Figure 1) and
could not be detected by routine chromosome banding
techniques because it is highly cryptic. Therefore, the
translocation is easily overlooked in conventional
cytogenetics.
By RACE PCR and sequencing a truncated version of
the NTRK3 transcript was found in the forward sequen-
cing reaction containing the polyA tail of the transcript,
whereas the reverse reaction identified ETV6 as the 5’
part of the transcript. NTRK3 is located on chromosome
15q25 which is affected in our patient as demonstrated
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reactions of RACE products, no partner gene on chro-
mosome 10 could be detected. Whole chromosome
paints of chromosomes 10 and 15 did not show any
translocated signals (data not shown).
Expression of the truncated fusion transcript and possi-
ble isoforms was tested in nested RT-PCR experiments
(see Figure 2). Results showed that ETV6 and the alterna-
tively spliced, truncated NTRK3 clearly exist as a fusion
transcript. Furthermore, the existence of ETV6 being
fused to catalytically active NTRK3 was proven. RT-
PCR amplification products of patient RNA were then
sequenced with appropriate primers. Based on these
results the proposed entire fusion transcripts contain
ETV6 exons 1 through 5 fused to NTRK3 exons 13b and
14b or NTRK3 exons 13 through 18 (see Figure 3). Both
NTRK3 i s o f o r m sa r ei n - f r a m ef u s i o np a r t n e r so fETV6.
No ETV6-NTRK3 transcripts could be detected in control
cDNA from patients without ETV6 rearrangement. The
reciprocal translocation product (NTRK3-ETV6) was not
detected on the RNA level when patient cDNA was
amplified with different primer combinations suggesting
its missing expression.
So far, catalytically active ETV6-NTRK3 fusion pro-
teins have been detected in a significant fraction of non-
hematopoietic tumors, e.g. secretory breast carcinoma,
congenital fibrosarcoma or mesoblastic nephroma
[11,12,14]. Their transforming ability is based on consti-
tutive activation of the NTRK3 moiety with downstream
activation of Ras- MAP kinase and phosphatidyl inosi-
tol-3-kinase (PI3K)-AKT pathways [11]. Interestingly,
the ETV6-NTRK3 fusion has been reported in only one
case of hematological malignancy, i.e. an AML (FAB
M2) [13]. Here, we describe the presence of the ETV6-
NTRK3 fusion in a further AML case which, in contrast
belongs to the FAB M0 subgroup. Furthermore, there
are two striking differences between the previously
detected hematological ETV6-NTRK3 fusion and the
one described here. In this context, one needs to point
out that ETV6 activity as a transcriptional repressor is
achieved by at least two different domains: the HLH
domain and the central region located between the
HLH and ETS domain encoded by part of exon 4 and
the entire exon 5 [1,2]. This central domain was shown
to interact with corepressors, whereas the HLH domain
represses gene transcription independently from core-
pressors [2,15]. As far as the differences are concerned,
the fusion transcript identified in this study exhibits
ETV6 exons 1 through 5 in contrast to the previously
Figure 1 FISH experiments. 1a. ETV6 break apart FISH. Arrows indicate the split signal for one allele, the arrow head marks the fusion signal of
the wildtype allele. 1b. WCP of chromosomes 12 (red) and 15 (green). The arrows indicate the reciprocal translocation giving rise to derivate
chromosomes der(12) and der(15). The arrow head marks the additional material of chromosome 12 on chromosome 10.
Figure 2 Nested RT-PCR of fusion transcripts. Results indicate
that ETV6 builds fusion transcripts with both the truncated and
catalytically active NTRK3 (lane numbers explained below). ETV6-
NTRK3 rearrangement: 1 control PCR of patient with ETV6-NTRK3-
rearrangement (ABL1); 2 ETV6 exon5 and NTRK3 exon14; 3 ETV6
exon5 and NTRK3 exon14I; 4 ETV6 exon5 and NTRK3 exon14II; 5 ETV6
exon5 and NTRK3 exon17; all NTRK3 primers are specific for the
tyrosine kinase domain. Controls: 6 control PCR of patient without
ETV6-NTRK3-rearrangement (ABL1); 7 ETV6 exon5 and NTRK3SequF
(patient without ETV6-NTRK3-rearrangement); 10 water control.
NTRK3-ETV6 Rearrangement: 8,9 NTRK3 exon12 (2 primers) and ETV6
exon6.
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exons. Therefore, the entire central domain, made up
partly of exon 4 and the entire exon 5, is still present
and might enable further protein-protein interactions.
The second difference is that ETV6 was shown to be
fused to the catalytically active isoform in the earlier
report. In our case we demonstrated that alternative
splicing of the transcribed ETV6-NTRK3 gene takes
p l a c ea n dg i v e sr i s et ot h et r u n c a t e dN T R K 3i s o f o r m
which is known to induce signaling that results in mem-
brane ruffling and cellular protrusions, structural
changes that support cell migration [16].
Unfortunately, insufficient patient material did not
allow the investigation of ETV6-NTRK3 expression on
the protein level. The oncogenic activity of both variants
remains to be revealed. Thereby one must keep in mind
that fusion products containing ETV6 have been shown
to involve diversely regulated aberrant mechanisms. As
far as kinase domain proteins are concerned, ETV6
influences the fusion partner’s activity via its HLH
(dimerization) domain [8]. Regarding the ETV6-NTRK3
fusion, data prove that the NTRK3 kinase domain by
itself does not provoke transformation activity. More
precisely, it was demonstrated that NIH3T3 cells cannot
be successfully transformed by ETV6-NTRK3 chimeric
proteins that still possess a perfectly operating NTRK3
kinase domain but lack a functional ETV6 HLH domain
[17]. In other rearrangements, the ETV6 promotor driv-
ing the transcription of the fusion gene is thought to
confer oncogenic potential [8]. It is possible that the
two variants of fusion products identified in this study
may function differently in cell transformation.
Conclusion
We described a novel ETV6 fusion with a gene involved
in neuronal development, NTRK3,i nA M L .T h ef u s i o n
gene has been previously detected in non-hematopoietic
tumors, e.g. secretory breast carcinoma and congenital
fibrosarcoma. Comparable to other molecular alterations
in AML the ETV6-NTRK3 fusion might be of prognostic
relevance and should be investigated further in larger
patient cohorts.
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